 Omega Diagnostics Group PLC
Annual Report and Group Financial Statements 2015 01
Overview
01 Operational and Financial Highlights
02 At a Glance
05 Our Strategy and Key Performance Indicators
06 Chairman’s Statement
Strategic Report
08 Our Business Model
10 Our Core Markets
12 Chief Executive’s Review
14 Our Business Model in Action
16 Risks and Risk Management
18 Financial Review
Governance
20 Board of Directors
22 Senior Management Team
23 Corporate Governance Report
25 Advisers
26 Directors’ Report
27  Directors’ Remuneration Report
29  Statement of Directors’ Responsibilities
Financial Statements
30 Independent Auditor’s Report
31  Consolidated Statement of Comprehensive Income
31 Adjusted Profit Before Taxation
32 Consolidated Balance Sheet
33  Consolidated Statement of Changes in Equity
34 Consolidated Cash Flow Statement
35 Company Balance Sheet
36 Company Statement of Changes in Equity
37 Company Cash Flow Statement
38 Notes to the Financial Statements
59 Notice of Annual General Meeting
60 Notes to the Notice of Annual General Meeting
Contents
   V i si t e c t
®
 CD4 test manufacturing process 
fully in-house following further recruitment 
to the scientific team.
   Engagement with experts in lateral 
flow diagnostics and completion of 
investigation phase for Visitect
®
 CD4.
   V i si t e c t
®
 CD4 final product stability being 
evaluated prior to further field evaluation.
   Continuing progress with allergy development 
programme with 32 allergens now optimised.
   Finished kits for 27 allergens available on the 
shelf and external site evaluations started.
   Appointment of Colin King as 
Chief Operating Officer from 3 August 2015.
   Manufacturing facility in Pune, 
India, progressing with fit-out 
substantially completed.
Operational Highlights
At a Glance
Page 2
Our Business Model
Page 8
Sales (£m)
£12.1m
2013 2014 2015
11.3
11.6
12.1
 4%
Adjusted profit before tax (£m)
£1.4m
0.8
1.1
1.4
2013 2014 2015
 25%
Gross profit (£m)
£7.7m
2013 2014 2015
7.1
7.4
7.7
 4%
Gross profit (%)
63.4%
2013 2014 2015
 0.2%
62.6
63.6 63.4
Financial Highlights
Overview
